Pharmaceuticals

Cytovance Biologics' new cell line service boasts top-tier yields. This strategic shift toward a 'one-stop-shop' model could redefine speed and cost in biopharma.

With a new $7.55M seed round, Rivvun AI is deploying autonomous agents to recover the billions lost in the gap between corporate contracts and payments.

NBA legend Shaquille O'Neal's campaign for Zepbound spotlights a silent health epidemic, but the drug's high cost and the ethics of celebrity ads loom large.

Soaring healthcare costs, fueled by GLP-1 drugs, have employers trapped. A new report shows why flexible benefits are becoming a critical survival strategy.

DuPont now powers its US healthcare plants with 100% renewables, a key move in a carbon-heavy sector. But a look behind the certificates reveals a complex strategy.

At EHA 2026, Parexel isn't just presenting data; it's unveiling a bold new strategy to fix a broken system and accelerate life-saving blood cancer drugs.

An expanded partnership between GENESIS Pharma and Alnylam is set to bring revolutionary RNAi therapies to the Nordics. But can it navigate the region's tough economic hurdles?

With its pivotal Phase 3 trial complete, Rafael Holdings is on a path to redefine treatment for NPC and transform itself into a commercial-stage biotech.

Organon's FDA nod for TOFIDENCE in critical care isn't just a clinical win. It's a calculated move to capture market share and challenge high-cost biologics.

New clinical data suggests Cullinan Therapeutics' cancer-fighting tech could offer durable, treatment-free remission for severe RA and lupus patients.

With $101M from top VCs, Ethyreal Bio emerges from stealth to target the root cause of both Graves' Disease and Thyroid Eye Disease with a single antibody.

A landmark deal sees Novartis invest up to $1.4B in Orionis Biosciences' AI platform, aiming to turn the chance discovery of 'molecular glue' drugs into a science.

A new deal brings a breakthrough blood cancer therapy, Zemcelpro®, closer to Canada. But for patients with few options, the 2028 timeline is a stark reminder of the gap between innovation and access.

Health Canada's Priority Review for a new Duchenne muscular dystrophy drug signals hope for patients and a strategic test of Canada's rare disease market.

A UK firm's regulatory milestone is more than just compliance; it's a strategic masterclass in building the resilient systems needed to fight food allergies.

Questex's Fierce Biotech is launching a UK event, but this is more than expansion. It’s a calculated bet on London's future as a biotech superpower.

A groundbreaking partnership between Servier and n-Lorem Foundation blends pharma R&D muscle with non-profit agility to develop ASO therapies for the rarest of diseases.

As new drugs outpace manufacturing capacity, a French giant bets on local production in China to build the supply chains of tomorrow's therapies.

Sanofi's promising nerve disease drug fails in late-stage trials, leaving vulnerable patients in limbo and highlighting the brutal realities of medical innovation.

Mickey Mikitani shifts to Executive Chairman, installing a new CEO to navigate the high-stakes journey from visionary science to U.S. market reality.